Amgen Inc. is on an upward trajectory, reflecting strong fundamentals and positive market sentiment.
Amgen Inc. (NASDAQ:AMGN) is rising today, with shares up 1.41%, closing at CA$411.76. This positive movement follows a series of favorable developments and strong performance indicators for the biotech giant.
Investor takeaway: Investors may find Amgen's consistent growth and solid fundamentals appealing, particularly in a market that favors dividend growth stocks amid rising interest rates.
Advertisement
Amgen Inc
AMGN.US
AMGN.US
Amgen Inc
WealthAwesomeMarket cap
$219.55B
P/E
25.5x
Div. yield
2.39%
Div. / share
$9.80
52W high
$447.03
52W low
$263.36
1W change
+6.91%
Beta
0.43
Analyst Price Targets
Based on 32 analysts covering AMGN · as of Sep 25, 2026
Wall Street analysts forecast AMGN stock price to rise 1194.4% over the next 12 months.
Consensus
Buy3.63 / 5.00
Avg. Target
C$389.22
+1194.4% Upside
Previously C$387.69 on Sep 21, 2026
Current Price
C$30.07
Last close
Analyst Breakdown (32 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on AMGN's historical volatility
30-Day Vol
40.3%
Annualized
90-Day Vol
33.2%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$485.42
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$430.94 | C$375.04 – C$495.18 |
| 60 trading days | C$457.37 | C$375.78 – C$556.68 |
| 90 trading days | C$485.42 | C$381.60 – C$617.50 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Amgen's Market Cap Reaches CA$219.52 Billion
With a P/E ratio of 25.25 and a profit margin of 22.95%, Amgen's financial health remains strong, making it a viable candidate for long-term investment.
Bull case
Amgen has shown impressive revenue growth, reporting a 9.5% year-over-year increase in its latest earnings. Analysts project a long-term earnings growth rate of 6%. The company is also known for its commitment to dividend growth, making it an attractive option for income-focused investors.
Bear case
Despite its strong fundamentals, Amgen faces challenges such as increased scrutiny over drug pricing and rising competition in the biotech sector. Investors should be cautious of potential regulatory hurdles that could affect future growth.
Advertisement
Strong Earnings Performance
Amgen reported impressive earnings, with revenues of $10.05 billion for the latest quarter, exceeding analysts' expectations by 6.9%. This performance highlights the company's ability to adapt and thrive in a competitive market, driven by its innovative therapies targeting serious illnesses.
Dividend Growth Appeal
Amgen's commitment to dividend growth is underscored by its current yield of 2.41%. As investors seek stability in uncertain markets, Amgen's history of increasing payouts positions it as a solid choice for those looking to balance income generation with long-term capital appreciation.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
